Format

Send to

Choose Destination
Reg Anesth Pain Med. 2019 Jul 8. pii: rapm-2019-100529. doi: 10.1136/rapm-2019-100529. [Epub ahead of print]

Botulinum toxin for chronic pelvic pain in women with endometriosis: a cohort study of a pain-focused treatment.

Author information

1
Intramural Research Program, Rehabilitation Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
2
Office of the Clinical Director, Intramural Research Program, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA strattop@mail.nih.gov.
3
Biostatistics and Clinical Epidemiology Service, Intramural Research Program, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
4
Office of the Clinical Director, Intramural Research Program, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.

Abstract

BACKGROUND AND OBJECTIVES:

Many women with endometriosis continue to have pelvic pain despite optimal surgical and hormonal treatment; some also have palpable pelvic floor muscle spasm. We describe changes in pain, spasm, and disability after pelvic muscle onabotulinumtoxinA injection in women with endometriosis-associated pelvic pain, a specific population not addressed in prior pelvic pain studies on botulinum toxin.

METHODS:

We present an open-label proof-of-concept case series of women with surgically diagnosed endometriosis. Under conscious sedation and with topical anesthetic, 100 units of onabotulinumtoxinA was injected transvaginally into pelvic floor muscle spasm areas under electromyography guidance. Changes in pain intensity, muscle spasm, disability, and pain medication use were assessed at periodic visits for up to 1 year after injection.

RESULTS:

Thirteen women underwent botulinum toxin injection and were followed for at least 4 months. Before injection, 11 of the 13 women had spasm in >4/6 assessed pelvic muscles and reported moderate pain (median visual analog scale (VAS): 5/10; range: 2-7). By 4-8 weeks after injection, spasm was absent/less widespread (≤3 muscles) in all (p=0.0005). Eleven rated their postinjection pain as absent/mild (median VAS: 2; range: 0-5; p<0.0001); 7/13 reduced pain medication. Disability decreased in 6/8 women with at least moderate preinjection disability (p=0.0033). Relief lasted 5-11 months in 7 of the 11 patients followed for up to 1 year. Adverse events were mild and transient.

CONCLUSIONS:

These findings suggest pelvic floor spasm may be a major contributor to endometriosis-associated pelvic pain. Botulinum toxin injection may provide meaningful relief of pain and associated disability.

TRIAL REGISTRATION NUMBER:

NCT01553201.

KEYWORDS:

botulinum toxin; chronic pelvic pain; endometriosis; muscle spasm; pelvic floor

PMID:
31289238
DOI:
10.1136/rapm-2019-100529

Conflict of interest statement

Competing interests: BIK is also an investigator on one study for which the NIH has received a grant from Allergan and another study for which the NIH has received a grant from Merz.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center